Tech-9094a: Licensing Opportunity: Endotoxin-binding Compounds for Sepsis (Orphan Drug Approval Pending)

 Specially Designed, Endotoxin-Binding Compounds for Treatment of Sepsis

Orphan Drug Approval Likely in Early 2020

Strategic Partnership / Licensing Opportunity

Our Client, a biotech company developing molecular medicine has developed novel therapeutic agents/compounds for the treatment of sepsis. The trigger for sepia and often resulting septic shock (dangerously low blood pressure), results from a massive immune system response usually caused by bacterial infection. The actual trigger of septic shock syndrome is endotoxins, also known as polyglycans or Lipopolysaccharides (LPS). Endotoxins or LPS, is the major component of the outer membranes of gram-negative bacteria.

According to one estimate, sepsis has a worldwide incidence of more than 20 million cases a year, with mortality due to septic shock reaching up to 50 percent even in industrialized countries. According to the U.S. Centers for Disease Control, septic shock is the thirteenth leading cause of death in the United States and the most frequent cause of deaths in intensive care units. There has been an increase in the rate of septic shock deaths in recent decades, which is attributed to an increase in invasive medical devices and procedures, increases in immunocompromised patients, and an overall increase in elderly patients. According to an August 2013 study conducted by the Agency for Healthcare Research and Quality, a division of the United States Department of Health and Human Services (HHS), sepsis is the most expensive condition treated in hospitals, with annual costs to the U.S healthcare system exceeding $20 billion. It accounted for 5.2% of the national costs for hospitalization in 2011, and also the most expensive condition billed to Medicare (6.9%).

Currently there is no effective treatment for Sepsis. The current protocol is to offer supportive care to alleviate the symptoms of sepsis. The last commercially available drug was Xigris which was removed from the market by Eli Lilly.

Our client Company has developed novel small peptides (11 or 12 amino acids long) created by rational design aimed at neutralizing the injurious effects of endotoxins by directly binding to them and stopping the cascade of events leading to septic shock and death. The Client is planning to conduct phase I trials shortly and is looking for licensing this opportunity.

Do contact us for more information on this technology and to connect with our client.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.